Physician profile
Lynn Mitchell
NPI 1457337404
$4,059.81
in general payments reported to CMS, 2019-2025
17 companies · $1,085 in 2025
The $1,085 reported for 2025 was more than what 82% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $538 · 2022: $612 · 2023: $887 · 2024: $938 · 2025: $1,085.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,910.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,909.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,052.73 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $671.39 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $484.67 | 2022-2025 | Uzedy, Austedo Xr, Austedo |
| Janssen Pharmaceuticals, INC | $325.01 | 2022-2025 | Spravato, Invega Sustenna |
| Lundbeck LLC | $308.36 | 2021-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $285.53 | 2021-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $252.42 | 2024-2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $187.29 | 2024-2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $145.20 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Axsome Therapeutics, INC. | $108.77 | 2023-2025 | Auvelity, Sunosi |
| Neurocrine Biosciences, INC. | $85.92 | 2023-2025 | Ingrezza |
| Idorsia Pharmaceuticals US INC | $44.80 | 2023 | Quviviq |
| Neuronetics, INC. | $27.66 | 2022 | |
| Sunovion Pharmaceuticals INC. | $21.49 | 2022 | |
| Hikma Pharmaceuticals USA | $20.88 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $19.51 | 2025 | Trintellix |
| Braeburn INC. | $18.18 | 2025 | Brixadi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lynn Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.